Drug · CHEMBL655

MIDAZOLAM

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. MIDAZOLAM. Drugs and targets, record CHEMBL655. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL655

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: MIDAZOLAM; ChEMBL
ChEMBL ID: CHEMBL655; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Midazolam in 0.8% sodium chloride, Midazolam in 0.9% sodium chloride, Nayzilam; ChEMBL
Other names: Midazolam civ, USL-261, USL261; ChEMBL
Other form: MIDAZOLAM HYDROCHLORIDE, CHEMBL1200420; Drugs and targets
Other form: MIDAZOLAM MALEATE, CHEMBL2106922; Drugs and targets
DrugBank: DB00683; DrugBank
InChIKey: DDLIGBOFAVUZHB-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 3 of its 80 diseases, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Targets16

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
GABRA1	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2554
GABRA2	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2555
GABRA3	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2556
GABRA4	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2557
GABRA5	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2558
GABRA6	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2559
GABRB1	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2560
GABRB2	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2561
GABRB3	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2562
GABRD	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2563

1 to 10 of 16Source ChEMBL

See all 16 targets

Diseases80

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
sedation	Phase 3	ClinicalTrials.gov	26	26	https://conductscience.org/library/drugs?q=EFO_0009868
anxiety	Phase 3	ClinicalTrials.gov	23	23	https://conductscience.org/library/drugs?q=MONDO_0011918
major depressive disorder	Phase 3	ClinicalTrials.gov	16	16	https://conductscience.org/library/drugs?q=MONDO_0002009
Agitation	Phase 3	ClinicalTrials.gov	10	10	https://conductscience.org/library/drugs?q=HP_0000713
depressive disorder	Phase 3	ClinicalTrials.gov	10	10	https://conductscience.org/library/drugs?q=MONDO_0002050
Pain	Phase 3	ClinicalTrials.gov	9	9	https://conductscience.org/library/drugs?q=HP_0012531
status epilepticus	Approval	DailyMed and PMDA	8	6	https://conductscience.org/library/drugs?q=EFO_0008526
delirium	Phase 3	ClinicalTrials.gov	6	6	https://conductscience.org/library/drugs?q=MONDO_0045057
post-traumatic stress disorder	Phase 3	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0005146
bipolar disorder	Phase 2	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0004985

1 to 10 of 80Source Open Targets

See all 80 diseases

Trials933

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00809146	Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications	Phase 3	1,023	2012-04-13	midazolam	Its name	ClinicalTrials.gov
NCT02937506	Patient Satisfaction With Propofol for Out Patient Colonoscopy	Phase 4	600	2017-09-27	midazolam	Its name	ClinicalTrials.gov
NCT00789815	Bispectral Index-guided Sedation for Flexible Bronchoscopy	Phase 4	500	2010-04-20	midazolam	Its name	ClinicalTrials.gov
NCT02290873	A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients	Phase 3	461	2018-11-09	midazolam	Its name	ClinicalTrials.gov
NCT00326612	Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures	Phase 2	358	2011-10-26	midazolam	Its name	ClinicalTrials.gov
NCT03246724	Oral Versus Intravenous Sedation for Ocular Procedures	Phase 4	327	2020-08-19	midazolam	Its name	ClinicalTrials.gov
NCT04807101	Sedation Regimens in GI Endoscopy	Early phase 1	300	2024-04-15	midazolam	Its name	ClinicalTrials.gov
NCT01390220	Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters	Phase 3	292	2019-05-31	midazolam	Its name	ClinicalTrials.gov
NCT01488045	Compare Propofol to Fentanyl and Midazolam for Colonoscopy		289	2023-05-23	midazolam	Its name	ClinicalTrials.gov
NCT01643616	Ultrasound Guided Distal Sciatic Nerve Block - a Comparison With Nerve Stimulator Technique		250	2013-11-01	midazolam	Its name	ClinicalTrials.gov

1 to 10 of 933

See all 933 trials

Comparisons in its trials193

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
IM Midazolam vs IV Lorazepam: serious adverse events	137 of 514	156 of 509	1,023	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects Admitted to an Intensive Care Unit (ICU)	128 of 448	161 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With Recurrent Seizure Within 12 Hours After ED Arrival	51 of 448	47 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With Endotracheal Intubation Within 30 Min After ED Arrival	63 of 448	64 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With Termination of Seizures at ED Arrival With no Rescue Therapy Given	329 of 448	282 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With Hypotension	12 of 448	13 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects Hospitalized	258 of 448	292 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With IM Injection-site Complications	4 of 448	2 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With IV Injection-site Complications	0 of 448	3 of 445	893	NCT00809146	Trial comparisons
Propofol vs Fentanyl Plus Midazolam Only: deaths from any cause	0 of 300	0 of 300	600	NCT02937506	Trial comparisons

1 to 10 of 193

See all 193 comparisons in its trials

Papers from its trials475

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41845869	RESULT	1	PubMed
41429434	RESULT	1	PubMed
40720114	RESULT	1	PubMed
40365924	RESULT	1	PubMed
39979559	RESULT	1	PubMed
39564442	RESULT	1	PubMed
38534990	RESULT	1	PubMed
38450918	RESULT	1	PubMed
38293492	RESULT	1	PubMed
37801625	RESULT	1	PubMed

1 to 10 of 475

See all 475 papers from its trials

Tests in its trials14

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Symbol Coding	3	2	ConductCognition
Choice Reaction Time	2	1	ConductCognition
Verbal Learning	2	1	ConductCognition
Dimensional Change Card Sort	1	0	ConductCognition
Clock Drawing Task	1	0	ConductCognition
Continuous Performance Test	1	0	ConductCognition
Free Recall Task	1	0	ConductCognition
Go/No-Go Task	1	0	ConductCognition
Mnemonic Similarity Task	1	0	ConductCognition
Paced Visual Serial Addition Test	1	1	ConductCognition

1 to 10 of 14

See all 14 tests in its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL655

GET https://conductscience.org/api/drugs/v1/CHEMBL655/diseases?page=2

API reference For AI assistants